Fukutome A, Matsumine T
Jpn J Antibiot. 1983 Aug;36(8):1999-2006.
Some 23 patients suffering from severe gastrointestinal infections were treated with cefoxitin (CFX) at the Bokuto Metropolitan Hospital, surgical ward, from September to November, 1982. Clinical examinations were conducted and the findings bacteriologically evaluated. The following clinical results were obtained: Of 23 patients, 11 were treated for diffuse peritonitis, 5 for localized peritonitis, and 7 for cholangitis. Following treatment, 5 were judged "excellent", 12 "good", 4 "fair", and 2 "poor." The clinical efficacy rate was 74%. Antibiotic disc susceptibility testings for ampicillin, cephalexin, gentamicin, and CFX were conducted. Gram-negative rods, such as E. coli, Klebsiella sp., Proteus sp., and especially, anaerobic B. fragilis, indicated susceptibility to CFX. B. fragilis was resistant to the remaining 3 antibiotics. Transient elevations in S-GOT and S-GPT levels were observed in 2 patients. However, this was not thought to be caused by CFX. No other irregularities were found. CFX is considered to be a drug of first choice for the treatment of severe gastrointestinal infections. However, for infections due to mixed Pseudomonas aeruginosa and other bacteria, concomitant treatment with CFX and an aminoglycoside is recommended.
1982年9月至11月期间，在博古都市立医院外科病房，对23名患有严重胃肠道感染的患者使用头孢西丁（CFX）进行了治疗。进行了临床检查，并对检查结果进行了细菌学评估。获得了以下临床结果：23名患者中，11名接受弥漫性腹膜炎治疗，5名接受局限性腹膜炎治疗，7名接受胆管炎治疗。治疗后，5名患者被判定为“优秀”，12名“良好”，4名“中等”，2名“较差”。临床有效率为74%。对氨苄西林、头孢氨苄、庆大霉素和CFX进行了抗生素纸片药敏试验。革兰氏阴性杆菌，如大肠杆菌、克雷伯菌属、变形杆菌属，尤其是脆弱拟杆菌，对CFX敏感。脆弱拟杆菌对其余3种抗生素耐药。2名患者出现谷草转氨酶（S-GOT）和谷丙转氨酶（S-GPT）水平短暂升高。然而，这并非认为是由CFX引起的。未发现其他异常情况。CFX被认为是治疗严重胃肠道感染的首选药物。然而，对于由铜绿假单胞菌和其他细菌混合感染引起的感染，建议联合使用CFX和氨基糖苷类药物进行治疗。
